Evidence map›Paper›PMID 25745148›Full record

ArticleScience (New York, N.Y.)2015

RNA interference. Drugging RNAi.

Dirk Haussecker, Mark A Kay

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Strategies for Testing Intervention Matching Schemes in Cancer.Clinical pharmacology and therapeutics · 2020
    Review
  5. Article
  6. Review
  7. Article
  8. The effector mechanism of siRNA spherical nucleic acids.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Advances in the clinical translation of nanotechnology.Current opinion in biotechnology · 2017
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dirk HausseckerRNAi Therapeutics Consulting, Rastatt, Germany. dirk.haussecker@gmail.com markay@stanford.edu.
Mark A KayPediatrics and Genetics, Stanford University, Stanford, CA, USA. dirk.haussecker@gmail.com markay@stanford.edu.

Funding

RNAi for the Treatment of Viral HepatitisR01AI071068 · NIAID · STANFORD UNIVERSITY · PI KAY, MARK A · 2006 to 2020
$6.7M
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseasesR37AI071068 · NIAID · STANFORD UNIVERSITY · PI Mark A Kay · 2021 to 2026
$4.3M
NIAID NIH HHS R01 AI071068NIAID NIH HHS R37 AI071068
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Delivery SystemsDrug DiscoveryRNA InterferenceAmyloid Neuropathies, FamilialCardiovascular DiseasesGene TargetingHepatitis BHumansLiverLiver NeoplasmsNanoparticlesPrealbuminRNA, Double-StrandedRNA, MessengerRNA, Small InterferingTemplates, GeneticPrealbuminRNA, Double-StrandedRNA, MessengerRNA, Small Interfering

Identifiers

PMID25745148
PMCPMC6018011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.